0001558370-23-000722.txt : 20230131 0001558370-23-000722.hdr.sgml : 20230131 20230131161516 ACCESSION NUMBER: 0001558370-23-000722 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230127 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230131 DATE AS OF CHANGE: 20230131 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptimmune Therapeutics PLC CENTRAL INDEX KEY: 0001621227 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37368 FILM NUMBER: 23572727 BUSINESS ADDRESS: STREET 1: 60 JUBILEE AVENUE STREET 2: MILTON PARK CITY: ABINGDON, OXFORDSHIRE STATE: X0 ZIP: OX14 4RX BUSINESS PHONE: 44 1235 430000 MAIL ADDRESS: STREET 1: 60 JUBILEE AVENUE STREET 2: MILTON PARK CITY: ABINGDON, OXFORDSHIRE STATE: X0 ZIP: OX14 4RX FORMER COMPANY: FORMER CONFORMED NAME: Adaptimmune Ltd DATE OF NAME CHANGE: 20141001 8-K 1 adap-20230127x8k.htm 8-K
0001621227false00-000000000016212272023-01-272023-01-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 27, 2023

ADAPTIMMUNE THERAPEUTICS PLC

(Exact name of registrant as specified in its charter)

England and Wales

1-37368

Not Applicable

(State or other jurisdiction of
incorporation)

(Commission File Number)

(IRS Employer Identification No.)

60 Jubilee Avenue, Milton Park

Abingdon, Oxfordshire OX14 4RX

United Kingdom

(Address of principal executive offices, including zip code)

(44) 1235 430000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which
registered

American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share

ADAP

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 1.02. Termination of a Material Definitive Agreement.

On January 27, 2023 Adaptimmune Therapeutics plc (“Adaptimmune”) received notice of termination of the Amended and Restated Research Collaboration and License Agreement Relating to Gene Editing and HLA Engineering Technology dated January 13, 2020 between Universal Cells, Inc. (“Universal Cells”) and Adaptimmune Limited (“Agreement”). Termination of the Agreement is effective 30 days following the receipt of notice of termination. Termination follows Adaptimmune’s decision to change the cell line being used to develop its MAGE-A4 allogeneic cell therapy due to the presence of a chromosomal abnormality in the original cell line provided by Universal Cells under the Agreement. As a result of termination, all licenses between the parties to the Agreement will cease and each party is requried to return all confidential information of the other party. A separate Collaboration and License Agreement dated January 13, 2020 for the co-development and co-commercialisation of allogeneic T-cell therapies remains ongoing between the parties.

Item 9.01    Financial Statements and Exhibits.

(d)  Exhibits.

Exhibit No.

    

Description of Exhibit

104

Cover Page Interactive Date File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ADAPTIMMUNE THERAPEUTICS PLC

Date: January 31, 2023

By:

/s/ Margaret Henry

Name:

Margaret Henry

Title:

Corporate Secretary

EX-101.SCH 2 adap-20230127.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 adap-20230127_lab.xml EX-101.LAB EX-101.PRE 4 adap-20230127_pre.xml EX-101.PRE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Jan. 27, 2023
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Jan. 27, 2023
Entity File Number 1-37368
Entity Registrant Name ADAPTIMMUNE THERAPEUTICS PLC
Entity Incorporation, State or Country Code X0
Entity Tax Identification Number 00-0000000
Entity Address, Address Line One 60 Jubilee Avenue
Entity Address, Adress Line Two Milton Park
Entity Address, City or Town Abingdon, Oxfordshire
Entity Address, Postal Zip Code OX14 4RX
Entity Address, Country GB
City Area Code 44
Local Phone Number 1235 430000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share
Trading Symbol ADAP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001621227
Amendment Flag false
XML 6 adap-20230127x8k_htm.xml IDEA: XBRL DOCUMENT 0001621227 2023-01-27 2023-01-27 0001621227 false 00-0000000 8-K 2023-01-27 ADAPTIMMUNE THERAPEUTICS PLC X0 1-37368 60 Jubilee Avenue Milton Park Abingdon, Oxfordshire OX14 4RX GB 44 1235 430000 false false false false American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share ADAP NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports adap-20230127x8k.htm adap-20230127.xsd adap-20230127_lab.xml adap-20230127_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "adap-20230127x8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "adap-20230127x8k.htm" ] }, "labelLink": { "local": [ "adap-20230127_lab.xml" ] }, "presentationLink": { "local": [ "adap-20230127_pre.xml" ] }, "schema": { "local": [ "adap-20230127.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "adap", "nsuri": "http://www.adaptimmune.com/20230127", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "adap-20230127x8k.htm", "contextRef": "Duration_1_27_2023_To_1_27_2023_m2v4O1C-_EaKExranpG3dg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "adap-20230127x8k.htm", "contextRef": "Duration_1_27_2023_To_1_27_2023_m2v4O1C-_EaKExranpG3dg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "adap_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.adaptimmune.com/20230127", "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Adress Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001558370-23-000722-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-000722-xbrl.zip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